Search
Amedalin
go.drugbank.com/drugs/DB09188ExperimentalIt has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.
MORF-057
go.drugbank.com/drugs/DB23674InvestigationalMORF-057 is under investigation in clinical trial NCT06226883 (A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease).
3'-deoxyguanosine
go.drugbank.com/drugs/DB03609ExperimentalThis compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar. This medication targets the protein purine nucleoside phosphorylase.
2-Methoxyestradiol
go.drugbank.com/drugs/DB02342Investigational2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).
Rilematovir
go.drugbank.com/drugs/DB15672InvestigationalRilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With
ILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.
ARC183
go.drugbank.com/drugs/DB05124ExperimentalARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).